Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | NPBWR1 | P48145 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.48 |
| ▸ | EIF4A1 | P60842 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26613519 | 0.81 | ABCG2 (0.47) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL29746264 | 0.81 | ABCG2 (0.47) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL9595911 | 0.81 | RAB9A (0.65) | NPC1RAB9AMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL20557641 | 0.80 | NPC1 (0.68) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL30469262 | 0.80 | NPC1 (0.68) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL7360004 | 0.80 | ELANE (0.43) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL28881645 | 0.80 | NPC1 (0.45) | ELANENPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL12814738 | 0.79 | NPC1 (0.71) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL1712398 | 0.79 | EIF4A1 (0.54) | ELANENPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL9164886 | 0.79 | ESR1 (0.55) | ELANENPC1RAB9AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2023-01-17 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2021-01-21 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696650-B2 | AHR inhibitors and uses thereof | Ikena Oncology, Inc. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3668496-A1 | AHR INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2020-06-24 | — | — | EP | disclosed |
| CN-111163766-A | AHR inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-105949118-B | A kind of preparation method of 2- aryl quinoline derivatives | 河南工业大学 | 2019-02-26 | — | — | CN | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | PAHR THERAPEUTICS, INC. | 2019-02-21 | — | — | US | disclosed |
| WO-2019036657-A1 | AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019036657-A1 | AHR INHIBITORS AND USES THEREOF | KYN THERAPEUTICS (US) | 2019-02-21 | — | — | WO | disclosed |
| CN-102083438-B | The quinoline of conditioning agent and related analogs as silent message regulatory factor | 西特里斯药业公司 | 2016-11-09 | — | — | CN | disclosed |
| CN-105949118-A | Preparation method of 2-aryl quinoline derivatives | 河南工业大学 | 2016-09-21 | — | — | CN | disclosed |
| CN-102083438-A | Quenolines and related analogs as sirtuin modulators | SIRTRIS PHARMACEUTICALS INC | 2011-06-01 | — | — | CN | disclosed |
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | MAKOVEC FRANCESCO | 2010-05-13 | — | — | US | disclosed |
| US-7674809-B2 | Anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM S.P.A. (IT) | 2010-03-09 | — | — | US | disclosed |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | ROTTAPHARM SPA | 2005-09-08 | — | — | US | disclosed |
| EP-1571142-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | Rottapharm S.p.A. (IT) | 2005-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555026-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | ELANE 1908/4885NPC1 2197/4885RAB9A 4623/4885 |
| US-20210017153-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | ELANE 1908/4885NPC1 2197/4885RAB9A 4623/4885 |
| US-20100120802-A1 | Novel Anti-Inflammatory and Analgesic Heterocyclic Amidines that Inhibit Nitrogen Oxide (NO) Production | NOS3, NOS1, NOS2 | ELANE 467/4885NPC1 4082/4885RAB9A 2198/4885 |
| US-20050197331-A1 | Novel anti-inflammatory and analgesic heterocyclic amidines that inhibit nitrogen oxide (NO) production | NOS3, NOS1, NOS2 | ELANE 467/4885NPC1 4082/4885RAB9A 2198/4885 |
| US-10696650-B2 | AHR inhibitors and uses thereof | AHR, ARNT, AIPL1 | ELANE 1908/4885NPC1 2197/4885RAB9A 4623/4885 |
| US-20190055218-A1 | AHR INHIBITORS AND USES THEREOF | AHR, ARNT, AIPL1 | ELANE 1908/4885NPC1 2197/4885RAB9A 4623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.